NASDAQ · Healthcare · Biotechnology
Immunome, Inc.
IMNM
Immunome, Inc. CEO Clay Siegall · Market cap $1.9B.
$19.96
+0.56 · +2.89%
52w hi $27.6552w lo $7.96
Off 52w high 33.5%
58
ROUTINE
Current InsiderScore
Corp · 90d
4
3 buys · 1 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
0
0 strong · 0 notable
Analyst consensus
Strong Buy
Avg PT $36.33
Section 01
Recent Form 4 filings
10 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Jun 05 | Jean Jacques Bienaime | Buy | 3,500 | $19.46 | +$68K | 36 | |
| Jun 05 | Jean Jacques Bienaime | Buy | 6,000 | $19.48 | +$117K | 56 | |
| May 15 | Jean Jacques Bienaime | Buy | 5,000 | $20.70 | +$104K | 58 | |
| Apr 02 | Max Rosett | Chief Financial Officer | Sell | 63,656 | $21.91 | −$1.39M | 51 |
| Mar 27 | Clay B Siegall | President and CEO | Buy | 25,450 | $19.67 | +$501K | 48 |
| Dec 30 | Clay B Siegall | President and CEO | Buy | 4,729 | $21.15 | +$100K | 45 |
| Dec 19 | Philip Tsai | Chief Technical Officer | Buy | 10,000 | $20.49 | +$205K | 58 |
| Dec 19 | Clay B Siegall | President and CEO | Buy | 7,278 | $20.48 | +$149K | 55 |
| Dec 18 | Clay B Siegall | President and CEO | Buy | 46,511 | $21.50 | +$1000K | 51 |
| Jun 03 | Jean Jacques Bienaime | Buy | 5,000 | $9.38 | +$47K | 37 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JulAugSepOctNovDecJanFebMarAprMayJun